DK2488513T3 - 2,6-Diaminopyridinforbindelser til behandling af sygdomme forbundet med amyloidproteiner eller til behandling af øjensygdomme - Google Patents
2,6-Diaminopyridinforbindelser til behandling af sygdomme forbundet med amyloidproteiner eller til behandling af øjensygdommeInfo
- Publication number
- DK2488513T3 DK2488513T3 DK10776598.4T DK10776598T DK2488513T3 DK 2488513 T3 DK2488513 T3 DK 2488513T3 DK 10776598 T DK10776598 T DK 10776598T DK 2488513 T3 DK2488513 T3 DK 2488513T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- diseases
- amyloid proteins
- compounds
- diseases associated
- Prior art date
Links
- 102000009091 Amyloidogenic Proteins Human genes 0.000 title abstract 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- VHNQIURBCCNWDN-UHFFFAOYSA-N pyridine-2,6-diamine Chemical class NC1=CC=CC(N)=N1 VHNQIURBCCNWDN-UHFFFAOYSA-N 0.000 title abstract 2
- 208000030533 eye disease Diseases 0.000 title 1
- 230000005856 abnormality Effects 0.000 abstract 2
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000035474 group of disease Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000000007 visual effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09173184A EP2311823A1 (en) | 2009-10-15 | 2009-10-15 | 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases |
| PCT/EP2010/065439 WO2011045383A2 (en) | 2009-10-15 | 2010-10-14 | 2, 6 -diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2488513T3 true DK2488513T3 (da) | 2018-01-29 |
Family
ID=41800516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10776598.4T DK2488513T3 (da) | 2009-10-15 | 2010-10-14 | 2,6-Diaminopyridinforbindelser til behandling af sygdomme forbundet med amyloidproteiner eller til behandling af øjensygdomme |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8916590B2 (da) |
| EP (2) | EP2311823A1 (da) |
| JP (1) | JP5662460B2 (da) |
| CN (2) | CN104262243B (da) |
| AU (1) | AU2010305770B2 (da) |
| BR (1) | BR112012008843B1 (da) |
| CA (1) | CA2777509C (da) |
| DK (1) | DK2488513T3 (da) |
| ES (1) | ES2657701T3 (da) |
| MX (1) | MX2012004388A (da) |
| NO (1) | NO2488513T3 (da) |
| RU (1) | RU2538208C2 (da) |
| WO (1) | WO2011045383A2 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2311823A1 (en) | 2009-10-15 | 2011-04-20 | AC Immune S.A. | 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases |
| MX2014014308A (es) * | 2012-05-30 | 2015-02-12 | Hoffmann La Roche | Pirrolidino heterociclos. |
| WO2017148904A1 (en) * | 2016-02-29 | 2017-09-08 | Franz Grus | Predictive markers useful in the treatment of wet age-related macular degeneration |
| CN106986876B (zh) * | 2017-03-20 | 2019-02-19 | 北京理工大学 | 一种靶向标记眼晶体上皮细胞的荧光探针、其制备及应用 |
| US12016885B2 (en) | 2018-11-06 | 2024-06-25 | Alsatech, Inc. | Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab |
| WO2021065898A1 (ja) | 2019-09-30 | 2021-04-08 | 日本ケミファ株式会社 | アゼパン誘導体 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023A (en) * | 1847-03-20 | Stocking-loom | ||
| BE606550A (da) * | 1960-07-27 | |||
| US3651023A (en) * | 1968-07-02 | 1972-03-21 | Stamicarbon | Preparation of polyamides with special properties |
| SU400583A1 (ru) | 1971-07-05 | 1973-10-01 | Донецкое отделение физико органической химии Института физической химии Украинской ССР | Способ получения 2, 3-бисметилал\инопиридина |
| JPS604171A (ja) | 1983-06-23 | 1985-01-10 | Showa Denko Kk | N−アルキルアミノピラゾ−ル誘導体とその製造法および除草剤 |
| DE69526973T3 (de) | 1994-10-21 | 2010-01-07 | Innogenetics N.V. | Sequenzen von hepatitis-c-virus genotype 7, und deren verwendung als vorbeugende, therapeutische und diagnostische mittel |
| DE69532817T2 (de) | 1994-11-10 | 2005-01-13 | Millenium Pharmaceuticals, Inc., Cambridge | Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose |
| US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
| RU2171252C2 (ru) | 1995-09-22 | 2001-07-27 | Вакунага Фармасьютикал КО., Лтд. | Аминосоединение для получения новых производных пиридонкарбоновой кислоты или их солей |
| US6385594B1 (en) | 1998-05-08 | 2002-05-07 | Lendingtree, Inc. | Method and computer network for co-ordinating a loan over the internet |
| US6436915B1 (en) * | 2000-04-07 | 2002-08-20 | Kinetek Pharmaceuticals, Inc. | Pyrazole compounds |
| SI1859798T1 (sl) | 2001-03-29 | 2016-07-29 | Eli Lilly And Company | N-(2-ariletil) benzil amini kot antagonisti 5-ht6 receptorja |
| AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
| US20030149038A1 (en) | 2001-11-09 | 2003-08-07 | The Regents Of The University Of California | Alpha-helix mimicry by a class of organic molecules |
| GB0128287D0 (en) | 2001-11-26 | 2002-01-16 | Smithkline Beecham Plc | Novel method and compounds |
| US7574396B2 (en) | 2001-12-04 | 2009-08-11 | Andrew Kalotay Associates, Inc. | Method of and apparatus for administering an asset-backed security using coupled lattice efficiency analysis |
| GB0206723D0 (en) | 2002-03-21 | 2002-05-01 | Glaxo Group Ltd | Novel compounds |
| DE10221052A1 (de) | 2002-05-10 | 2003-12-04 | Transmit Technologietransfer | Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten |
| AU2003276919B2 (en) | 2002-09-25 | 2013-05-16 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| WO2004058239A1 (en) | 2002-12-24 | 2004-07-15 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20040205019A1 (en) | 2003-04-08 | 2004-10-14 | Lendingtree, Inc. | Method and system for selecting qualification forms for financial services and financial products |
| EP1628666B1 (en) | 2003-05-14 | 2015-09-23 | NeuroGenetic Pharmaceuticals, Inc. | Compouds and uses thereof in modulating amyloid beta |
| WO2004110354A2 (en) * | 2003-05-15 | 2004-12-23 | Roskamp Research, Llc | Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
| RU2336270C2 (ru) | 2003-06-30 | 2008-10-20 | Дайити Фармасьютикал Ко., Лтд. | Гетероциклические метилсульфоновые производные |
| TWI301760B (en) * | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
| SI1809622T1 (sl) | 2004-09-22 | 2010-11-30 | Janssen Pharmaceutica Nv | Inhibitorji interakcije med MDM in P |
| WO2006039327A2 (en) | 2004-10-01 | 2006-04-13 | Merck & Co., Inc. | Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve |
| JP2008523139A (ja) | 2004-12-14 | 2008-07-03 | アストラゼネカ・アクチエボラーグ | 置換アミノピリジン類及びその使用 |
| US20070073504A1 (en) | 2005-09-26 | 2007-03-29 | Bristol-Myers Squibb Company | Configurable component handling device |
| US7882025B1 (en) | 2005-11-18 | 2011-02-01 | Federal Home Loan Mortgage Corporation (Freddie Mac) | Systems and methods of a mortgage pricing service |
| SG172617A1 (en) | 2005-12-12 | 2011-07-28 | Ac Immune Sa | Therapeutic vaccine |
| MX2008007477A (es) | 2005-12-12 | 2008-09-03 | Ac Immune Sa | Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas. |
| EP1829867A1 (en) | 2006-03-03 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Imidazole compounds having pharmaceutical activity towards the sigma receptor |
| EP3279663B1 (en) * | 2006-03-15 | 2021-07-28 | The Brigham and Women's Hospital, Inc. | Use of gelsolin to diagnose and treat inflammatory diseases |
| NZ574188A (en) | 2006-07-14 | 2012-05-25 | Ac Immune Sa | Humanized antibody against amyloid beta |
| US20080109347A1 (en) | 2006-08-22 | 2008-05-08 | Pilcher John W | System and methods for constructing loans |
| BRPI0719379A2 (pt) * | 2006-11-24 | 2014-02-11 | Ac Immune Sa | Composto, composição farmacêutica, uso de composto, mistura, métodos para coletar dados para o diagnóstico de uma doença ou condição associada com amilóide em uma amostra ou um paciente, para determinar a extensão da carga de placa amiloidogênica em um tecido e/ou um fluido corporal, para coletar dados para determinar a predisposição a uma doença ou condição associada com amilóide em um paciente, para coletar dados para monitorar a doença residual mínima em um paciente seguindo o tratamento com um anticorpo ou uma composição de vacina e para coletar dados para predizer a responsividade de um paciente sendo tratado com um anticorpo ou uma composição de vacina, e, kit de teste |
| US8084613B2 (en) * | 2007-05-14 | 2011-12-27 | Nippon Soda Co., Ltd. | Tetrazoyloxime derivative and plant disease control agent |
| US8244618B1 (en) | 2009-01-08 | 2012-08-14 | Amherst Holdings, LLC | Loan information analysis system and method |
| EP2311823A1 (en) * | 2009-10-15 | 2011-04-20 | AC Immune S.A. | 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases |
-
2009
- 2009-10-15 EP EP09173184A patent/EP2311823A1/en not_active Withdrawn
-
2010
- 2010-10-14 EP EP10776598.4A patent/EP2488513B1/en active Active
- 2010-10-14 NO NO10776598A patent/NO2488513T3/no unknown
- 2010-10-14 RU RU2012119757/04A patent/RU2538208C2/ru active
- 2010-10-14 ES ES10776598.4T patent/ES2657701T3/es active Active
- 2010-10-14 AU AU2010305770A patent/AU2010305770B2/en not_active Ceased
- 2010-10-14 WO PCT/EP2010/065439 patent/WO2011045383A2/en not_active Ceased
- 2010-10-14 CA CA2777509A patent/CA2777509C/en active Active
- 2010-10-14 BR BR112012008843-2A patent/BR112012008843B1/pt not_active IP Right Cessation
- 2010-10-14 MX MX2012004388A patent/MX2012004388A/es active IP Right Grant
- 2010-10-14 DK DK10776598.4T patent/DK2488513T3/da active
- 2010-10-14 CN CN201410407476.7A patent/CN104262243B/zh not_active Expired - Fee Related
- 2010-10-14 JP JP2012533632A patent/JP5662460B2/ja not_active Expired - Fee Related
- 2010-10-14 CN CN201080056685.1A patent/CN102656161B/zh not_active Expired - Fee Related
- 2010-10-15 US US12/905,356 patent/US8916590B2/en active Active
-
2014
- 2014-09-30 US US14/502,907 patent/US9701660B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011045383A3 (en) | 2011-06-30 |
| EP2488513B1 (en) | 2017-12-27 |
| RU2538208C2 (ru) | 2015-01-10 |
| CN104262243A (zh) | 2015-01-07 |
| BR112012008843B1 (pt) | 2022-08-30 |
| CN102656161A (zh) | 2012-09-05 |
| CA2777509A1 (en) | 2011-04-21 |
| US8916590B2 (en) | 2014-12-23 |
| US20150023950A1 (en) | 2015-01-22 |
| AU2010305770A1 (en) | 2012-05-03 |
| CN102656161B (zh) | 2015-02-18 |
| MX2012004388A (es) | 2012-06-08 |
| CA2777509C (en) | 2015-06-02 |
| US9701660B2 (en) | 2017-07-11 |
| CN104262243B (zh) | 2017-04-12 |
| JP2013507428A (ja) | 2013-03-04 |
| EP2311823A1 (en) | 2011-04-20 |
| EP2488513A2 (en) | 2012-08-22 |
| WO2011045383A2 (en) | 2011-04-21 |
| AU2010305770B2 (en) | 2014-05-22 |
| JP5662460B2 (ja) | 2015-01-28 |
| RU2012119757A (ru) | 2013-11-20 |
| NO2488513T3 (da) | 2018-05-26 |
| BR112012008843A2 (pt) | 2022-02-08 |
| ES2657701T3 (es) | 2018-03-06 |
| US20110092537A1 (en) | 2011-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mangialasche et al. | Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment | |
| NZ602777A (en) | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | |
| DK2375907T3 (da) | Behandling af sygdomme, lidelser eller tilstande i lungerne under anvendelse af placentaceller | |
| IL260585B (en) | Compositions and methods for treating retinal diseases | |
| WO2012097213A3 (en) | Methods for diagnosing and treating eye-length related disorders | |
| CA2883095C (en) | Antibody and protein formulations | |
| IL287032A (en) | Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes | |
| HK1250238A1 (zh) | 抗angptl8抗体及其用途 | |
| WO2013049234A3 (en) | Dual function proteins for treating metabolic disorders | |
| PH12016500866A1 (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
| WO2014204816A3 (en) | Method for assessing protein identity and stability | |
| DK2470191T3 (da) | Fremgangsmåder og præparater til forebyggelse eller behandling af oftalmiske tilstande | |
| WO2016005466A3 (en) | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES | |
| WO2012045882A3 (en) | Phosphospecific antibodies recognising tau | |
| NO20092633L (no) | Ernaeringstilskuddsammensetning for behandling av okulare sykdommer | |
| WO2008029276A8 (en) | Compositions and methods for the treatment of ophthalmic disease | |
| WO2016040891A3 (en) | In vitro compositions comprising human sample and amyloid targeting agent | |
| EP3351211C0 (en) | SCLERAL PROSTHESIS TO TREAT PRESBYOPIA AND OTHER EYE DISORDERS | |
| IL209336B (en) | Compositions for treating hyperproliferative diseases and uses thereof | |
| MX2011010353A (es) | Composicion farmaceutica. | |
| CA2863417A1 (en) | Innate immune proteins as biomarkers for cns injury | |
| EP3290514A4 (en) | APPLICATION OF PI4KIII PROTEIN AND ASSOCIATED MEMBRANE PROTEIN COMPLEX IN THE TREATMENT OF MORBUS ALZHEIMER | |
| WO2011022357A3 (en) | Fast acting snare-cleaving enzymes | |
| WO2011045383A3 (en) | 2, 6 -diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases | |
| WO2008127654A3 (en) | Methods and compositions for intra-articular coagulation proteins |